Immutep's Efti In Combination With KEYTRUDA Generates Overall Survival Benefit In Patients With Metastatic Non-Small Cell Lung Cancer
Portfolio Pulse from Happy Mohamed
Immutep Limited (NASDAQ:IMMP) has announced promising clinical data from the TACTI-002 / KEYNOTE-798 Phase II trial evaluating eftilagimod alpha (efti) in combination with Merck & Co., Inc.'s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA as a first-line treatment for patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC). The data shows promising overall survival, overall response rate, progression free survival, and duration of response across all PD-L1 subgroups. Immutep plans to launch a Phase III trial next year.
October 23, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's efti shows promising results in combination with Merck's KEYTRUDA in Phase II trial for NSCLC treatment. This could potentially boost the company's stock.
The positive results from the Phase II trial could increase investor confidence in Immutep, potentially leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Merck's KEYTRUDA was used in combination with Immutep's efti in a Phase II trial for NSCLC treatment, showing promising results.
The positive results from the Phase II trial could increase investor confidence in Merck, potentially leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80